IJGC Podcast

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Drs. Oliver Zivanovic and Roisin O'Cearbhaill. Dr. Roisin O’Cearbhaill, MD, is a medical oncologist and the Research Director of the Gynecologic Medical Oncology Service and the Clinical Director of the Solid Tumor Program, Cellular Therapy Service at Memorial Sloan Kettering Cancer Center, with a joint faculty appointment at Weill Cornell Medical College. Nationally, she serves as the Chair, Developmental Therapeutics, NRG Oncology. Dr. Oliver Zivanovic MD is a Gynecologic Oncologist at the Department of Surgery at Memorial Sloan Ketteting Cancer Center with a joint faculty appointment at Weill Cornell Medical College. He serves as the Institutional Principle Investigator for NRG Oncology.

@ROCearbhaill / @zivanovicmd / @TeamOvary_MSK / @sloan_kettering

Highlights:

-HIPEC with carboplatin at secondary cytoreductive surgery for first platinum-sensitive recurrent ovarian cancer was not superior to secondary cytoreduction without HIPEC.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Professor Christina Fotopoulou to discuss the ESGO Guidelines on Perioperative Management Ovarian Cancer. Professor Fotopoulou is the lead author of “European Society of Gynaecological Oncology guidelines for the peri-operative management of patients with ovarian cancer,” which is the Lead Article of IJGC’s September 2021 issue. Professor Fotopoulou works at the Department of Surgery and Cancer at Imperial College London, UK. She is an elected ESGO council member and Chair of the ESGO guidelines committee.

Highlights

- Patients with advanced ovarian cancer need to have a holistic care assessment and detailed discussion about risks and benefits of surgical treatment tailored to their individual profile.

- A multidisciplinary team approach and complications management is crucial for the safe delivery of cytoreductive procedures

- Maximal infrastructural expertise and specialization are keys to surgical success

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. James Stuart Ferriss to discuss advances and novel approaches in uterine serous cancers. Dr. Ferriss is an assistant professor in the Kelly Gynecologic Oncology division, Department of Gynecology and Obstetrics, Johns Hopkins School of Medicine. He is the program director of the Montz fellowship in gynecologic oncology.

Highlights:

•Uterine serous carcinomas represent less than 10% of all uterine cancers, but 39% of disease specific deaths.

•Surgery remains the cornerstone of treatment.

•Our understanding of the molecular drivers of this uncommon cancer supports new, targeted therapies.

•Adjuvant treatment of advanced and recurrent uterine serous carcinomas should be based on HER2 expression.

In this episode of the IJGC podcast, Professor Ignace Vergote joins us for the Mentor’s Podcast. Professor Ignace Vergote is Chairman of the Department of Gynaecology and Obstetrics at the Catholic University Leuven since 2003. He published more than 900 papers on gynecologic cancer in peer-reviewed journals and his work has been cited more than 50,000 times. He served as President of IGCS, ESGO, EORTC-GCG and ENGOT.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Drs. Rebecca Previs and Benjamin Albright to discuss primary cytoreduction for advanced endometrial cancer. Dr. Rebecca Previs is an assistant professor within the Division of Gynecologic Oncology and the Department of Obstetrics & Gynecologic at Duke University Medical Center, Duke Cancer Institute in Durham, NC. Her translational research interests include understanding how the immune microenvironment and molecular characterization of gynecologic cancers influences disease biology and treatment outcomes. Outside of medicine, she enjoys spending time with her menagerie of pets, gardening, hiking, harvesting honey from her bee hives, and playing the piano. Dr. Ben Albright is a second-year fellow within the Division of Gynecologic Oncology and the Department of Obstetrics & Gynecologic at Duke University Medical Center, Duke Cancer Institute in Durham, NC. His research interests include health policy and economics, health services research, systematic review, and cost-effectiveness analysis. Outside of medicine, he enjoys trail running, tennis, hiking with his wife and two big dogs, and University of Kentucky basketball.

@BeccaPrevisMD / @BenAlbrightMD / @dukeobgyn / @DukeCancer

Highlights

1. The objective of our study was (1) to assess the frequency of reported proportions of maximal (R0, no gross residual disease) and optimal (5. Women with advanced stage endometrial cancer should be encouraged to enroll on clinical trials when available.